[HTML][HTML] Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima… - Nature medicine, 2023 - nature.com
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
D Kotani, E Oki, Y Nakamura, H Yukami… - Nature …, 2023 - europepmc.org
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
[HTML][HTML] Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami… - Nature …, 2023 - ncbi.nlm.nih.gov
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami… - Nature …, 2023 - kyushu-u.elsevierpure.com
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami… - Nature …, 2023 - pubmed.ncbi.nlm.nih.gov
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima… - Nature Medicine, 2023 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Despite standard-of-care treatment, more than
30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA …
30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA …